Thyrocare Posts Strong Q2 FY27 Results and Divests Nueclear Healthcare
Thyrocare Technologies Ltd 路 Investor Presentation 路 29 Oct 2026, 9:47 pm
Thyrocare Posts Strong Q2 FY27 Results and Divests Nueclear Healthcare Thyrocare reported Q2 FY27 consolidated revenue of INR 270.8 Cr (+25.1% YoY) and EBITDA of INR 89.3 Cr (+25.0% YoY) with a 33.0% margin. PAT before exceptions grew 25.7% YoY to INR 60.2 Cr, while reported PAT fell to INR 15.2 Cr due to a one-time INR 45.0 Cr goodwill impairment from divesting Nueclear Healthcare (NHL) for INR 141.4 Cr. Total active franchisees reached 12,911 (+27.1% YoY) and tests performed rose 27.4% YoY to 61.6 Mn. The company remains debt-free.
Original exchange filing (PDF)
More announcements from Thyrocare Technologies Ltd
- Please find the enclosed announcement. 路 06 Nov 2026
- Please find the enclosed intimation. 路 06 Nov 2026
- Please find attached the Earnings Call Transcript held on October 29, 2026 路 02 Nov 2026
- Please find attached Intimation regarding the Execution of Share Purchase Agreement 路 30 Oct 2026
- Audio Recording of Earnings Conference Call for the Quarter and Half Year Ended September 30, 2026 路 30 Oct 2026
- Please find attached the Press Release on the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
- Please find enclosed the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
- Please find enclosed outcome of the Board Meeting held on October 29, 2026, inter alia, approving the unaudited financial results for the quarter and half year ended September 30, 2026 .... 路 29 Oct 2026
